Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-29
2011-03-29
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S050000, C514S051000
Reexamination Certificate
active
07915233
ABSTRACT:
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.
REFERENCES:
patent: 4789666 (1988-12-01), Gennari
patent: 4960759 (1990-10-01), De Luca et al.
patent: 5470838 (1995-11-01), Von Borstel et al.
patent: 5583117 (1996-12-01), von Borstel et al.
patent: 5691320 (1997-11-01), Von Borstel et al.
patent: 5906996 (1999-05-01), Murphy
patent: 5968914 (1999-10-01), von Borstel et al.
patent: 5981601 (1999-11-01), Nagley et al.
patent: 6258795 (2001-07-01), von Borstel et al.
patent: 6316426 (2001-11-01), von Borstel et al.
patent: 6472378 (2002-10-01), von Borstel
patent: 2001/0005719 (2001-06-01), Von Borstel
patent: 2002/0028787 (2002-03-01), Watkins et al.
patent: 2004/0224920 (2004-11-01), Naviaux
patent: 0 462 075 (1991-12-01), None
patent: 817 877 (1959-08-01), None
patent: 817877 (1959-08-01), None
patent: 62-12794 (1987-01-01), None
patent: 4-243830 (1992-08-01), None
patent: 7-228535 (1995-08-01), None
patent: 10-505578 (1998-06-01), None
patent: WO 96/14063 (1996-05-01), None
patent: WO 97/45127 (1997-12-01), None
patent: WO 00/06174 (2000-02-01), None
patent: 00/50043 (2000-08-01), None
Page, Theodore et al., “Developmental disorder associated with increased cellular nucleotidase activity,” Proceedings of the National Academy of Science USA, Oct. 1997, 94 (21), 11601-11606.
Przyrembel J. Inher. Metab. Dis. (1987), vol. 10, pp. 129-146.
Sengers et al. Eur. J. Pediatr. (1984), vol. 141, pp. 192-207.
Secades et al.; CDP-Choline: Pharmacoligical and Clinical Review. Methods and Findings in Experimental and Clinical Pharmacology. Oct. 1995, vol. 17, Supplement 1, pp. 1-54.
Database Medline on STN AN 94049698, Keilbaugh et al. Anti-human Immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2', 3'-dideoxy cytidine toxicity in PC 12 cells, a neuronal model, by uridine and pyruvate. Molecular Pharmacology. Oct. 1993. vol. 44. No. 4. pp. 702-706.
Dykens, J.A. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated Ca2+ and Na+: Implications for neurodegeneration. Journal of Neurochemistry. 1994, vol. 63, pp. 584-591.
Bodnar et al. Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochem. J. 1995, vol. 305, pp. 817-822.
Morais, R., and Guertin, D.,Can. J. Biochem., vol. 60, p. 290-294, 1982 “On the contribution of the mitochondrial genome to the growth of Chinese hamster embryo cells in culture”.
Morais, R., et al,In Vitro Cellular&Development Biology, vol. 24, No. 7, Jul. 1988, p. 649-658, “Development and Characterization of Continuous Avian Cell Lines Depleted of Mitochondrial DNA”.
Bourgeron, Thomas, et al,The Journal of Biological Chemistry, vol. 268, No. 26, Sep. 15, 1993, pp. 19369-19376, “Fate and expression of the deleted mitochondrial DNA differ between human heteroplasmic skin fibroblast and Epstein-Barr virus-transformed lymphocyte cultures”.
Löffler, Monika, et al,Molecular and Cellular Biochemistry, 174:125-192, 1997, “Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides”.
Page, Theodore, et al,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 11601-11606, Oct. 1997, “Development disorder associated with increased cellular nucloetidase activity”.
Keilbaugh et al (Mol. Pharm. 44: 702-706, abstract only (1995).
Kralovansky et al., “Cancer Chemotherapy and Pharmacology,” 32: 243-248, see abstract, lines 4-7 (1993).
Lipp et al, Biology of the Neonate 33: 62-65, see entire abstract (1978).
Sartori et al, Alcohol 3:97-100, see first and last sentences of abstract (1986).
Agnati et al, Acta Phys. Scanda, 126: 525-531, see abstract, lines 5-15 (1986).
Chen et al; “Effect of Anti-Human Immunodeficiency Virus Nucleoside Analogs on Mitochondrial DNA and Its Implication for Delayed Toxicity”; Molec. Pharmacol; 39:625-628; (1991).
Keilbaugh et al; “Anti-Human Immunodeficiency Virus Type 1 Therapy and Peripheral Neuropathy: Prevention of 2′3′-Dideoxycytidine Toxicity in PC12 Cells, A Neuronal Model, by Uridine and Pyruvate”; Molec. Pharmacol. 44:702-706 (1993).
DiMauro, S., et al; “Mitochondrial Encephalomyopathies: Where Next?”;1999 Revista De Neurologia; vol. 28, No. 2; pp. 164-158.
Luft, R., “The development of mitochondrial medicine”;Proc. Natl. Acad. Sci.; vol. 91, pp. 8731-8738 (1994).
Beal, M.F., “Mitochondrial dysfunction in neurodegenerative diseases”;Biochimica et Biophysica Acta; 1366, pp. 211-223 (1998).
Blass, J.P., “Brain Metabolism and Brain Disease: Is Metabolic Deficiency the Proximate Cause of Alzheimer Dementia?”;Journal of Neuroscience Research; vol. 66; pp. 851-856 (2001).
Bowling, A.C., et al; “Bioenergetic and Oxidative Stress in Neurodegenerative Diseases”;Life Sciences, vol. 56, No. 14, pp. 1151-1171 (1995).
Beal, M.F., “Mitochondria, free radicals, and neurodegeneration”;Current Opinion in Neurobiology; vol. 6, pp. 661-666 (1996).
Browne, S.E., et al; “Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases”;Biochemical Society Transactions; vol. 22, 5 pages (1994).
Schulz, J.B., et al; “Mitochondrial dysfunction in movement disorders”;Current Opinion in Neurology; vol. 7; pp. 333-339 (1994).
Page, T., et al; “A Syndrome of Megaloblastic Anemia, Immunodeficiency, and Excessive Nucleotide Degradation”;Purine and Pyrimidine Metabolism in Man VII, Part B; pp. 345-348 (1991).
Page, T., et al; “A Syndrome of Seizures and Pervasive Development Disorder Associated with Excessive Cellular Nucleotidase Activity”;Purine and Pyrimidine Metabolism in Man IX; pp. 789-792 (1998).
Ferrante, R.J., et al; “Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease”;The Journal of Neuroscience; 20(12), pp. 4389-4397, Jun. 15, 2000.
Du, Y., et al; “Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease”;PNAS, vol. 98, No. 25; pp. 14469-14674 (Dec. 4, 2001).
Ravina, B.M., et al; “Neuroprotective Agents for Clinical Trials in Parkinson's Disease”;American Academy of Neurology; 60, pp. 1234-1240 (2003).
Vary, “Increased pyruvate dehydrogenase kinase activity in response to sepsis”, Am. J. Physiol. (May 1991; 160 (5 Pt 1): E669-74.
Office Action issued by European Patent Office Communication pursuant to Article 96(2) EPC; European Patent Application No. 99 968 207.3—2123 dated Aug. 24, 2007 (6 pgs).
Cacabelos, R., et al; “Therapeutic Effects of CDP-Choline in Alzheimer's Disease Cognition, Brain Mapping, Cerebrovascular Hemodynamics, and Immune Factors”;Annals New York Academy of Sciences; The Neurobiology of Alzheimer's Disease; pp. 399-403 (1996) XP008065562.
Pecori, J., et al; “Systemic administration of a neurotrophic drug in the complementary treatment of glaucomatous optic neuropathy”;New Trends in Ophthalmology; vol. IX, No. 2; pp. 85-91 (1994) XP008065559.
Office Action issued in corresponding Korean Patent Application No. 2007-7017066, dated Oct. 19, 2007 with English translation (10 pgs).
Bodnar, A.G., et al; “Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication”;Biochem. J.; 305, pp. 817-822 (1995).
Official Action issued in corresponding Japanese Patent Application No. 2000-567085, dated Dec. 18, 2009 with English translation (19 pgs).
Schapira, A.H.V.; “Mitochondrial dysfunction in neurodegenerative disorders”;Biochimica et Biophysics Acta, 1366, pp. 225-233 (1998).
Schapira, A.H.V.; “Human complex I defects in
Lewis Patrick T
Nixon & Vanderhye
Wellstat Therapeutics Corporation
LandOfFree
Compositions and methods for treatment of mitochondrial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of mitochondrial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of mitochondrial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699767